Biohaven Ltd. (BHVN)

NYQ – Real vaqt narxi. Valyuta: USD

9.20

+0.12 (1.32%)

Yopilishda: May 12, 2026, 4:00 PM EDT

05.05.2026

Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why

Biohaven Ltd. (BHVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

04.05.2026

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026. Advancement of high-value, late-stage priority programs: Pivotal epilepsy program with selective Kv7 ion channel activator, opakalim, with expected topline results in 2H 2026.

15.04.2026

Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026

Biohaven Ltd. is downgraded from Strong Buy to Hold following the FDA's Complete Response Letter for troriluzole in Spinocerebellar Ataxia. BHVN pivots focus to three late-stage programs: MODE/TRAP degraders [BHV-1400, BHV-1300], Kv7 activator Opakalim, and myostatin-activin inhibitor taldefgrobep alfa for obesity. Taldefgrobep alfa targets obesity with a novel MOA aiming for fat loss, muscle gain, and improved safety versus GLP-1s; phase 2 POC data is expected in 2H 2026.

13.04.2026

Why Biohaven Stock Crushed it on Monday

That pundit flagged the stock as a buy. He also expects it to more than double in price.

23.03.2026

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Sarissa Capital Management added 513,184 shares in Biohaven during the fourth quarter. The quarter-end position value increased by $5.79 million as a result of the transaction.

21.03.2026

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash

DAFNA Capital Management bought 720,000 shares of Biohaven in the fourth quarter; the estimated trade size was $8.92 million, based on average prices in the fourth quarter of 2025. Meanwhile, the quarter-end value of the position rose by $7.25 million, reflecting both the share increase and stock price changes during the period.

19.03.2026

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity.

Videolar

No Data

There is no data to display

Press-relizlar

04.05.2026

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

19.03.2026

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

02.03.2026

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular protein degradation for immunological diseases, Kv7 ion channel modulation for epilepsy; and myostatin-activin pathway targeting obesity: Inflammation and Immunology: Graves' Disease: First-in-patient clinical experience with IgG MoDE degrader BHV-1300 resulted in complete suppression of disease-causing TSH receptor-stimulating antibodies, normalization of previously elevated thyroid hormones within weeks after dosing a patient with Graves' disease. BHV-1300 has shown the potential for best-in-class reductions of IgG, with maximum reductions of up to an 87% decrease from baseline within weeks of dosing in a study conducted in healthy volunteers.

12.01.2026

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ degraders exclusively licensed from Yale University. Early clinical experience in patients demonstrates rapid removal of circulating disease-causing proteins, resulting in robust clinical improvement with a well-tolerated profile to date: IgA Nephropathy (IgAN) Program: First dosing of BHV-1400 TRAP degrader in IgAN patients achieved early observations of both biomarker and clinical responses including: selective lowering of only the disease-causing galactose-deficient IgA1 (Gd-IgA1) while sparing off-target effects on healthy antibodies (IgA, IgM, IgE, IgG), resolution of blood in the urine (hematuria), deep reductions in proteinuria, and improvement in fatigue and kidney function (eGFR) within weeks.

Biohaven Ltd. (BHVN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Biohaven Ltd. (BHVN)

Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026

Why Biohaven Stock Crushed it on Monday

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Videolar

No Data

Press-relizlar

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026

Why Biohaven Stock Crushed it on Monday

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Videolar

No Data

Press-relizlar

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Search stocks

Biohaven Ltd. (BHVN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Biohaven Ltd. (BHVN)

Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026

Why Biohaven Stock Crushed it on Monday

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Videolar

No Data

Press-relizlar

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026

Why Biohaven Stock Crushed it on Monday

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Videolar

No Data

Press-relizlar

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference